Trials / Completed
CompletedNCT00612703
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Erlotinib in Adult Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety, tolerability and recommended Phase 2 dose of ARQ 197 when administered in combination with erlotinib to patients with advanced solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ 197 | Treatment with ARQ 197 in combination with erlotinib |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2010-09-01
- First posted
- 2008-02-12
- Last updated
- 2012-07-23
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00612703. Inclusion in this directory is not an endorsement.